Circulatory support for long-term treatment of Heart failure: Experience with an intraventricular continuous flow pump
A lifetime mechanical solution for advanced heart failure must be reliable, with a low risk of life-threatening complications. After extensive laboratory testing, we began clinical trials with an axial flow pump for long-term treatment of New York Heart Association class IV, transplant-ineligible pa...
Gespeichert in:
| Veröffentlicht in: | Circulation (New York, N.Y.) N.Y.), 2002-06, Vol.105 (22), p.2588-2591 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2591 |
|---|---|
| container_issue | 22 |
| container_start_page | 2588 |
| container_title | Circulation (New York, N.Y.) |
| container_volume | 105 |
| creator | WESTABY, Stephen BANNING, Adrian P JARVIK, Robert FRAZIER, O. H SAITO, Satoshi PIGOTT, David W JIN, Xu Y CATARINO, Pedro A ROBSON, Desiree MOORJANI, Narain KARDOS, Attila POOLE-WILSON, Philip A |
| description | A lifetime mechanical solution for advanced heart failure must be reliable, with a low risk of life-threatening complications. After extensive laboratory testing, we began clinical trials with an axial flow pump for long-term treatment of New York Heart Association class IV, transplant-ineligible patients.
The Jarvik 2000 is a continuous flow device that is implanted in the apex of the left ventricle with offloading to the descending thoracic aorta. Skull-based percutaneous power delivery was derived from cochlear implant technology. We used this system in 4 patients with end-stage dilated cardiomyopathy. Exercise capacity, quality of life, device parameters, and native heart function were monitored serially. One patient died from right heart failure at 3 months. The other patients were discharged from hospital between 3 and 8 weeks postoperatively and are currently New York Heart Association I or II. Follow-up lasted between 9 and 20 months. There has been no device failure or hemolysis. Native heart function and quality of life were markedly improved.
The Jarvik 2000 is a true assist (rather than replacement) device that functions synergistically with the native left ventricle and provides excellent quality of life. Adverse events are infrequent. This blood pump may provide a mechanical solution for end-stage heart failure in the community. |
| doi_str_mv | 10.1161/01.CIR.0000018165.24503.5B |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71786043</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>126995871</sourcerecordid><originalsourceid>FETCH-LOGICAL-c358t-5c078150216bb664a35e72337ec77c6fd049f2b56923b9baaa7b3f025d2585cb3</originalsourceid><addsrcrecordid>eNpdkV1rFDEUhoModq3-BQkFvZsx35npnV1qWygIotchk000ZSYZ89GPf2-2XVgwN4dwnvOeAw8AZxj1GAv8BeF-e_OjR_uHByx4TxhHtOcXr8AGc8I6xun4Gmxaf-wkJeQEvMv5rn0FlfwtOMEEMd6iNuB-65Opsy4xPcFc1zWmAl1McI7hd1dsWmBJVpfFhgKjg9dW7wHt55rsObx8XG3yNhgLH3z5A3WAPpSk7xue_D44QRND8aHGmqGb4wNc67K-B2-cnrP9cKin4Ne3y5_b6-72-9XN9uttZygfSscNkgPmiGAxTUIwTbmVhFJpjZRGuB1ioyMTFyOh0zhpreVEHSJ8R_jAzURPweeX3DXFv9XmohafjZ1nHWw7SEksB4EYbeDZf-BdrCm02xTBRDLKKW7Q-QtkUsw5WafW5BednhRGaq9GIayaGnVUo57VKH7Rhj8eNtRpsbvj6MFFAz4dAJ2Nnl3Swfh85KjElI2I_gO52Zin</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>212743531</pqid></control><display><type>article</type><title>Circulatory support for long-term treatment of Heart failure: Experience with an intraventricular continuous flow pump</title><source>MEDLINE</source><source>American Heart Association Journals</source><source>Journals@Ovid Complete</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>WESTABY, Stephen ; BANNING, Adrian P ; JARVIK, Robert ; FRAZIER, O. H ; SAITO, Satoshi ; PIGOTT, David W ; JIN, Xu Y ; CATARINO, Pedro A ; ROBSON, Desiree ; MOORJANI, Narain ; KARDOS, Attila ; POOLE-WILSON, Philip A</creator><creatorcontrib>WESTABY, Stephen ; BANNING, Adrian P ; JARVIK, Robert ; FRAZIER, O. H ; SAITO, Satoshi ; PIGOTT, David W ; JIN, Xu Y ; CATARINO, Pedro A ; ROBSON, Desiree ; MOORJANI, Narain ; KARDOS, Attila ; POOLE-WILSON, Philip A</creatorcontrib><description>A lifetime mechanical solution for advanced heart failure must be reliable, with a low risk of life-threatening complications. After extensive laboratory testing, we began clinical trials with an axial flow pump for long-term treatment of New York Heart Association class IV, transplant-ineligible patients.
The Jarvik 2000 is a continuous flow device that is implanted in the apex of the left ventricle with offloading to the descending thoracic aorta. Skull-based percutaneous power delivery was derived from cochlear implant technology. We used this system in 4 patients with end-stage dilated cardiomyopathy. Exercise capacity, quality of life, device parameters, and native heart function were monitored serially. One patient died from right heart failure at 3 months. The other patients were discharged from hospital between 3 and 8 weeks postoperatively and are currently New York Heart Association I or II. Follow-up lasted between 9 and 20 months. There has been no device failure or hemolysis. Native heart function and quality of life were markedly improved.
The Jarvik 2000 is a true assist (rather than replacement) device that functions synergistically with the native left ventricle and provides excellent quality of life. Adverse events are infrequent. This blood pump may provide a mechanical solution for end-stage heart failure in the community.</description><identifier>ISSN: 0009-7322</identifier><identifier>EISSN: 1524-4539</identifier><identifier>DOI: 10.1161/01.CIR.0000018165.24503.5B</identifier><identifier>PMID: 12045161</identifier><identifier>CODEN: CIRCAZ</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams & Wilkins</publisher><subject>Adrenergic beta-Antagonists - therapeutic use ; Aged ; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Angiotensin-Converting Enzyme Inhibitors - therapeutic use ; Biological and medical sciences ; Body Weight ; Cardiac Surgical Procedures - adverse effects ; Cardiomyopathy, Dilated - complications ; Cardiomyopathy, Dilated - therapy ; Echocardiography ; Emergency and intensive cardiocirculatory care. Cardiogenic shock. Coronary intensive care ; Equipment Design ; Exercise Tolerance ; Follow-Up Studies ; Heart Failure - complications ; Heart Failure - therapy ; Heart Function Tests ; Heart Ventricles - diagnostic imaging ; Heart Ventricles - physiopathology ; Heart Ventricles - surgery ; Heart-Assist Devices - adverse effects ; Humans ; Intensive care medicine ; Male ; Medical sciences ; Middle Aged ; Postoperative Complications ; Quality of Life ; Recovery of Function ; Survival Rate ; Thrombosis - prevention & control ; Time ; Treatment Outcome ; Ventricular Dysfunction - complications ; Ventricular Dysfunction - therapy</subject><ispartof>Circulation (New York, N.Y.), 2002-06, Vol.105 (22), p.2588-2591</ispartof><rights>2002 INIST-CNRS</rights><rights>Copyright American Heart Association, Inc. Jun 4, 2002</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c358t-5c078150216bb664a35e72337ec77c6fd049f2b56923b9baaa7b3f025d2585cb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,3687,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13713490$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12045161$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>WESTABY, Stephen</creatorcontrib><creatorcontrib>BANNING, Adrian P</creatorcontrib><creatorcontrib>JARVIK, Robert</creatorcontrib><creatorcontrib>FRAZIER, O. H</creatorcontrib><creatorcontrib>SAITO, Satoshi</creatorcontrib><creatorcontrib>PIGOTT, David W</creatorcontrib><creatorcontrib>JIN, Xu Y</creatorcontrib><creatorcontrib>CATARINO, Pedro A</creatorcontrib><creatorcontrib>ROBSON, Desiree</creatorcontrib><creatorcontrib>MOORJANI, Narain</creatorcontrib><creatorcontrib>KARDOS, Attila</creatorcontrib><creatorcontrib>POOLE-WILSON, Philip A</creatorcontrib><title>Circulatory support for long-term treatment of Heart failure: Experience with an intraventricular continuous flow pump</title><title>Circulation (New York, N.Y.)</title><addtitle>Circulation</addtitle><description>A lifetime mechanical solution for advanced heart failure must be reliable, with a low risk of life-threatening complications. After extensive laboratory testing, we began clinical trials with an axial flow pump for long-term treatment of New York Heart Association class IV, transplant-ineligible patients.
The Jarvik 2000 is a continuous flow device that is implanted in the apex of the left ventricle with offloading to the descending thoracic aorta. Skull-based percutaneous power delivery was derived from cochlear implant technology. We used this system in 4 patients with end-stage dilated cardiomyopathy. Exercise capacity, quality of life, device parameters, and native heart function were monitored serially. One patient died from right heart failure at 3 months. The other patients were discharged from hospital between 3 and 8 weeks postoperatively and are currently New York Heart Association I or II. Follow-up lasted between 9 and 20 months. There has been no device failure or hemolysis. Native heart function and quality of life were markedly improved.
The Jarvik 2000 is a true assist (rather than replacement) device that functions synergistically with the native left ventricle and provides excellent quality of life. Adverse events are infrequent. This blood pump may provide a mechanical solution for end-stage heart failure in the community.</description><subject>Adrenergic beta-Antagonists - therapeutic use</subject><subject>Aged</subject><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Angiotensin-Converting Enzyme Inhibitors - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Body Weight</subject><subject>Cardiac Surgical Procedures - adverse effects</subject><subject>Cardiomyopathy, Dilated - complications</subject><subject>Cardiomyopathy, Dilated - therapy</subject><subject>Echocardiography</subject><subject>Emergency and intensive cardiocirculatory care. Cardiogenic shock. Coronary intensive care</subject><subject>Equipment Design</subject><subject>Exercise Tolerance</subject><subject>Follow-Up Studies</subject><subject>Heart Failure - complications</subject><subject>Heart Failure - therapy</subject><subject>Heart Function Tests</subject><subject>Heart Ventricles - diagnostic imaging</subject><subject>Heart Ventricles - physiopathology</subject><subject>Heart Ventricles - surgery</subject><subject>Heart-Assist Devices - adverse effects</subject><subject>Humans</subject><subject>Intensive care medicine</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Postoperative Complications</subject><subject>Quality of Life</subject><subject>Recovery of Function</subject><subject>Survival Rate</subject><subject>Thrombosis - prevention & control</subject><subject>Time</subject><subject>Treatment Outcome</subject><subject>Ventricular Dysfunction - complications</subject><subject>Ventricular Dysfunction - therapy</subject><issn>0009-7322</issn><issn>1524-4539</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkV1rFDEUhoModq3-BQkFvZsx35npnV1qWygIotchk000ZSYZ89GPf2-2XVgwN4dwnvOeAw8AZxj1GAv8BeF-e_OjR_uHByx4TxhHtOcXr8AGc8I6xun4Gmxaf-wkJeQEvMv5rn0FlfwtOMEEMd6iNuB-65Opsy4xPcFc1zWmAl1McI7hd1dsWmBJVpfFhgKjg9dW7wHt55rsObx8XG3yNhgLH3z5A3WAPpSk7xue_D44QRND8aHGmqGb4wNc67K-B2-cnrP9cKin4Ne3y5_b6-72-9XN9uttZygfSscNkgPmiGAxTUIwTbmVhFJpjZRGuB1ioyMTFyOh0zhpreVEHSJ8R_jAzURPweeX3DXFv9XmohafjZ1nHWw7SEksB4EYbeDZf-BdrCm02xTBRDLKKW7Q-QtkUsw5WafW5BednhRGaq9GIayaGnVUo57VKH7Rhj8eNtRpsbvj6MFFAz4dAJ2Nnl3Swfh85KjElI2I_gO52Zin</recordid><startdate>20020604</startdate><enddate>20020604</enddate><creator>WESTABY, Stephen</creator><creator>BANNING, Adrian P</creator><creator>JARVIK, Robert</creator><creator>FRAZIER, O. H</creator><creator>SAITO, Satoshi</creator><creator>PIGOTT, David W</creator><creator>JIN, Xu Y</creator><creator>CATARINO, Pedro A</creator><creator>ROBSON, Desiree</creator><creator>MOORJANI, Narain</creator><creator>KARDOS, Attila</creator><creator>POOLE-WILSON, Philip A</creator><general>Lippincott Williams & Wilkins</general><general>American Heart Association, Inc</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>U9A</scope><scope>7X8</scope></search><sort><creationdate>20020604</creationdate><title>Circulatory support for long-term treatment of Heart failure: Experience with an intraventricular continuous flow pump</title><author>WESTABY, Stephen ; BANNING, Adrian P ; JARVIK, Robert ; FRAZIER, O. H ; SAITO, Satoshi ; PIGOTT, David W ; JIN, Xu Y ; CATARINO, Pedro A ; ROBSON, Desiree ; MOORJANI, Narain ; KARDOS, Attila ; POOLE-WILSON, Philip A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c358t-5c078150216bb664a35e72337ec77c6fd049f2b56923b9baaa7b3f025d2585cb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Adrenergic beta-Antagonists - therapeutic use</topic><topic>Aged</topic><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Angiotensin-Converting Enzyme Inhibitors - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Body Weight</topic><topic>Cardiac Surgical Procedures - adverse effects</topic><topic>Cardiomyopathy, Dilated - complications</topic><topic>Cardiomyopathy, Dilated - therapy</topic><topic>Echocardiography</topic><topic>Emergency and intensive cardiocirculatory care. Cardiogenic shock. Coronary intensive care</topic><topic>Equipment Design</topic><topic>Exercise Tolerance</topic><topic>Follow-Up Studies</topic><topic>Heart Failure - complications</topic><topic>Heart Failure - therapy</topic><topic>Heart Function Tests</topic><topic>Heart Ventricles - diagnostic imaging</topic><topic>Heart Ventricles - physiopathology</topic><topic>Heart Ventricles - surgery</topic><topic>Heart-Assist Devices - adverse effects</topic><topic>Humans</topic><topic>Intensive care medicine</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Postoperative Complications</topic><topic>Quality of Life</topic><topic>Recovery of Function</topic><topic>Survival Rate</topic><topic>Thrombosis - prevention & control</topic><topic>Time</topic><topic>Treatment Outcome</topic><topic>Ventricular Dysfunction - complications</topic><topic>Ventricular Dysfunction - therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>WESTABY, Stephen</creatorcontrib><creatorcontrib>BANNING, Adrian P</creatorcontrib><creatorcontrib>JARVIK, Robert</creatorcontrib><creatorcontrib>FRAZIER, O. H</creatorcontrib><creatorcontrib>SAITO, Satoshi</creatorcontrib><creatorcontrib>PIGOTT, David W</creatorcontrib><creatorcontrib>JIN, Xu Y</creatorcontrib><creatorcontrib>CATARINO, Pedro A</creatorcontrib><creatorcontrib>ROBSON, Desiree</creatorcontrib><creatorcontrib>MOORJANI, Narain</creatorcontrib><creatorcontrib>KARDOS, Attila</creatorcontrib><creatorcontrib>POOLE-WILSON, Philip A</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Circulation (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>WESTABY, Stephen</au><au>BANNING, Adrian P</au><au>JARVIK, Robert</au><au>FRAZIER, O. H</au><au>SAITO, Satoshi</au><au>PIGOTT, David W</au><au>JIN, Xu Y</au><au>CATARINO, Pedro A</au><au>ROBSON, Desiree</au><au>MOORJANI, Narain</au><au>KARDOS, Attila</au><au>POOLE-WILSON, Philip A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Circulatory support for long-term treatment of Heart failure: Experience with an intraventricular continuous flow pump</atitle><jtitle>Circulation (New York, N.Y.)</jtitle><addtitle>Circulation</addtitle><date>2002-06-04</date><risdate>2002</risdate><volume>105</volume><issue>22</issue><spage>2588</spage><epage>2591</epage><pages>2588-2591</pages><issn>0009-7322</issn><eissn>1524-4539</eissn><coden>CIRCAZ</coden><abstract>A lifetime mechanical solution for advanced heart failure must be reliable, with a low risk of life-threatening complications. After extensive laboratory testing, we began clinical trials with an axial flow pump for long-term treatment of New York Heart Association class IV, transplant-ineligible patients.
The Jarvik 2000 is a continuous flow device that is implanted in the apex of the left ventricle with offloading to the descending thoracic aorta. Skull-based percutaneous power delivery was derived from cochlear implant technology. We used this system in 4 patients with end-stage dilated cardiomyopathy. Exercise capacity, quality of life, device parameters, and native heart function were monitored serially. One patient died from right heart failure at 3 months. The other patients were discharged from hospital between 3 and 8 weeks postoperatively and are currently New York Heart Association I or II. Follow-up lasted between 9 and 20 months. There has been no device failure or hemolysis. Native heart function and quality of life were markedly improved.
The Jarvik 2000 is a true assist (rather than replacement) device that functions synergistically with the native left ventricle and provides excellent quality of life. Adverse events are infrequent. This blood pump may provide a mechanical solution for end-stage heart failure in the community.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams & Wilkins</pub><pmid>12045161</pmid><doi>10.1161/01.CIR.0000018165.24503.5B</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0009-7322 |
| ispartof | Circulation (New York, N.Y.), 2002-06, Vol.105 (22), p.2588-2591 |
| issn | 0009-7322 1524-4539 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71786043 |
| source | MEDLINE; American Heart Association Journals; Journals@Ovid Complete; EZB-FREE-00999 freely available EZB journals |
| subjects | Adrenergic beta-Antagonists - therapeutic use Aged Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Angiotensin-Converting Enzyme Inhibitors - therapeutic use Biological and medical sciences Body Weight Cardiac Surgical Procedures - adverse effects Cardiomyopathy, Dilated - complications Cardiomyopathy, Dilated - therapy Echocardiography Emergency and intensive cardiocirculatory care. Cardiogenic shock. Coronary intensive care Equipment Design Exercise Tolerance Follow-Up Studies Heart Failure - complications Heart Failure - therapy Heart Function Tests Heart Ventricles - diagnostic imaging Heart Ventricles - physiopathology Heart Ventricles - surgery Heart-Assist Devices - adverse effects Humans Intensive care medicine Male Medical sciences Middle Aged Postoperative Complications Quality of Life Recovery of Function Survival Rate Thrombosis - prevention & control Time Treatment Outcome Ventricular Dysfunction - complications Ventricular Dysfunction - therapy |
| title | Circulatory support for long-term treatment of Heart failure: Experience with an intraventricular continuous flow pump |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T11%3A43%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Circulatory%20support%20for%20long-term%20treatment%20of%20Heart%20failure:%20Experience%20with%20an%20intraventricular%20continuous%20flow%20pump&rft.jtitle=Circulation%20(New%20York,%20N.Y.)&rft.au=WESTABY,%20Stephen&rft.date=2002-06-04&rft.volume=105&rft.issue=22&rft.spage=2588&rft.epage=2591&rft.pages=2588-2591&rft.issn=0009-7322&rft.eissn=1524-4539&rft.coden=CIRCAZ&rft_id=info:doi/10.1161/01.CIR.0000018165.24503.5B&rft_dat=%3Cproquest_cross%3E126995871%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=212743531&rft_id=info:pmid/12045161&rfr_iscdi=true |